



US04/33521



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ


REC'D 24 NOV 2004	
WIPO	PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *Andrew Gorse*
Dated 20 August 2004

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

Patents Act 1977
(Rule 16)



The Patent Office

1/77

15OCT03 E844603-1 D02029
P01/7700 0.00-0324086.8

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your Reference	SJB/PB60536P		
2. Patent application number (The Patent office will fill in this part)	0324086.8		14 OCT 2003
3. Full name, address and postcode of the or of each applicant (underline all surnames)	GLAXO GROUP LIMITED GLAXO WELLCOME HOUSE BERKELEY AVENUE GREENFORD MIDDLESEX UB6 ONN GB Patents ADP number (if you know it) 473587003 If the applicant is a corporate body, give the country/state of its corporation GB		
4. Title of the invention	PROCESS FOR PREPARING A CO-PRECIPITATE OF A NON-CRYSTALLINE SOLID DRUG SUBSTANCE		
5. Name of your agent (if you know one)	SUZANNE BAKER		
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode) Patents ADP number (if you know it)	GLAXOSMITHKLINE CORPORATE INTELLECTUAL PROPERTY (CN9 25.1) 980 GREAT WEST ROAD BRENTFORD MIDDLESEX TW8 9GS 8072355006		
6. If you are declaring priority from one or more earlier patent applications, give the country and date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of Filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day / month / year)
8. Is a statement of inventorship and of right to grant a patent required in support of this request? (Answer yes if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body.	YES		

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Description	32
Claim(s)	6
Abstract	1
Drawing(s)	2 only <i>lk</i>

10. If you are also filing any of the following, state how many against each item

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patent Form 9/77*)

Request for substantive examination (*Patent Form 10/77*)

Any other documents
(please specify)

11. I/We request the grant of a patent on the basis of this application

Suzanne Baker

Signature **SUZANNE BAKER** 14 October 2003
AGENT FOR THE APPLICANTS

12. Name and daytime telephone number of person to contact in the United Kingdom
- AMANDA WILKINSON**
020 8047 4493

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication of communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the patent Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been received

a) Notes

If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

b) *Write your answers in capital letters using black ink or you may type them.*

c) *If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form*

If you have answered "Yes" Patents Form 7/77 will need to be filed.

d) *Once you have filled in the form you must remember to sign and date it.*

e) *For details of the fee and ways to pay please contact the Patent Office.*

PROCESS FOR PREPARING A CO-PRECIPITATE OF A NON-CRYSTALLINE SOLID DRUG SUBSTANCE

BACKGROUND OF THE INVENTION

- 5 A co-precipitate is a type of solid dispersion of a drug substance which is produced by jointly precipitating from solution the drug substance together with a carrier, such as a polymer. Co-precipitates have been employed in the pharmaceutical industry to improve the oral bioavailability of sparingly soluble drug substances. Ohm, *European J. Pharmaceutics and Biopharmaceutics*
- 10 **49**:183-189 (2000). Nifedipine (ADALAT T10®) is an example of this approach. One method for forming a co-precipitate involves solubilizing both the drug substance and the carrier (e.g. polyvinylpyrrolidone (PVP)) in an organic solvent and then removing the solvent to cause the co-precipitation of the drug substance and carrier. This technique typically results in an intimate
- 15 mixture of the drug substance and the carrier in the final product. Examples of co-precipitates in the pharmaceutical industry are described in EP Patent No. 828479 to Glaxo, PCT Publication No. WO02/038127 to Bradford, and PCT Publication No. WO01/03821 to Bradford.
- 20 While co-precipitates have been employed to improve oral bioavailability of drug substances, it is believed that no literature methods exist for co-precipitation techniques which can improve the physical or handling properties of drug substances which exhibit poor handling properties. For example, it would be desirable to provide a method for improving the physical
- 25 properties of a non-particulate, non-crystalline solid drug substance, such as a wax-like drug substance, to provide the drug substance in the form of a free-flowing particulate material which is more conveniently handled using conventional pharmaceutical formulating techniques.
- 30 (E)-4-(1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid nonaethylene glycol methyl ether ester, methods for its

preparation and use and pharmaceutical formulations containing the same are disclosed in PCT Publication No. 98/35966, published 20 August 1998 and U.S. Patent No. 6,355,646 to Daluge et al. The compound is a waxy solid.

BRIEF SUMMARY OF THE INVENTION

5 As a first aspect the present invention provides a process for preparing a particulate form of a non-crystalline, solid drug substance. The process comprises the steps of:

- a) slowly adding a co-precipitant solution comprising the drug substance and a co-precipitating excipient solubilized in a non-aqueous solvent, to a
10 slurry comprising a core excipient dispersed in an anti-solvent, to prepare a co-precipitate, wherein the non-aqueous solvent and the anti-solvent are miscible; and
- b) isolating the co-precipitate.

15 As a second aspect, the present invention provides a process for improving the physical properties of a non-particulate, solid drug substance. The process comprises slowly adding a co-precipitant solution comprising the drug substance and a co-precipitating excipient solubilized in a non-aqueous solvent, to a slurry comprising a core excipient dispersed in an anti-solvent, to
20 prepare a co-precipitate, wherein the non-aqueous solvent and the anti-solvent are miscible.

As a third aspect, the present invention provides a process for preparing a co-precipitate of a non-crystalline, solid drug substance. The process comprises
25 slowly adding a co-precipitant solution comprising the drug substance and a co-precipitating excipient solubilized in a non-aqueous solvent, to a slurry comprising a core excipient dispersed in an anti-solvent, wherein the non-aqueous solvent and the anti-solvent are miscible.

30 As a fourth aspect, the present invention provides a pharmaceutical composition comprising a co-precipitate having a core and one or more drug

layers distributed around the core. The core comprises core excipient. The drug layers comprise a drug substance and a co-precipitating excipient. The co-precipitate is prepared by slowly adding a co-precipitant solution comprising the drug substance and the co-precipitating excipient solubilized in a non-aqueous solvent, to a slurry comprising the core excipient dispersed in an anti-solvent, wherein the non-aqueous solvent and the anti-solvent are miscible.

As a fifth aspect, the present invention provides a pharmaceutical composition comprising a co-precipitate having a core comprising a core excipient and one or more drug layers distributed around the core wherein the drug layers comprise (E)-4-(1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnaemic acid nonaethylene glycol methyl ether ester or a solvate thereof and a co-precipitating excipient.

As a sixth aspect, the present invention provides a process for preparing an aqueous-based pharmaceutical formulation comprising a non-crystalline, solid drug substance having low solubility in aqueous media. The process comprises the steps of:

- a) slowly adding a co-precipitant solution comprising the drug substance and a co-precipitating excipient solubilized in a non-aqueous solvent, to a slurry comprising a core excipient dispersed in an anti-solvent, to prepare a co-precipitate, wherein the non-aqueous solvent and the anti-solvent are miscible;
- b) isolating the co-precipitate; and
- c) admixing the co-precipitate with a pharmaceutically acceptable aqueous media to provide an aqueous-based pharmaceutical formulation.

In another aspect, the present invention provides a solid particulate drug substance produced by the process comprising the steps of:

- a) slowly adding a co-precipitant solution comprising the drug substance and a co-precipitating excipient solubilized in a non-aqueous solvent, to a

slurry comprising a core excipient dispersed in an anti-solvent, to prepare a co-precipitate, wherein the non-aqueous solvent and the anti-solvent are miscible; and

- b) isolating the co-precipitate.

5

As another aspect, the present invention provides another process for preparing a particulate form of a non-crystalline, solid drug substance. The process comprises the steps of:

- a) solubilizing the drug substance in a drug solvent to prepare a drug solution;

10

- b) admixing the drug solution with an anti-solvent to prepare a drug suspension comprising the drug substance suspended in a mixture of the drug solvent and the anti-solvent, wherein the drug solvent and the anti-solvent are miscible;

15

- c) slowly adding to the drug suspension, an excipient solution comprising a co-precipitating excipient solubilized in a non-aqueous solvent, to prepare a co-precipitate, wherein the non-aqueous solvent is miscible with the drug solvent and the anti-solvent; and

- d) isolating the co-precipitate.

20

As another aspect, the present invention provides another process for improving the physical properties of a non-particulate, solid drug substance. The process comprises the steps of:

- a) solubilizing the drug substance in a drug solvent to prepare a drug solution;

25

- b) admixing the drug solution with an anti-solvent to prepare a drug suspension comprising the drug substance suspended in a mixture of the drug solvent and the anti-solvent, wherein the drug solvent and the anti-solvent are miscible;

30

- c) slowly adding to the drug suspension, an excipient solution comprising a co-precipitating excipient solubilized in a non-aqueous solvent, to

prepare a co-precipitate, wherein the non-aqueous solvent is miscible with the drug solvent and the anti-solvent.

As another aspect, the present invention provides another process for preparing a co-precipitate of a non-crystalline, solid drug substance. The process comprises the steps of:

- a) solubilizing the drug substance in a drug solvent to prepare a drug solution;
- b) admixing the drug solution with an anti-solvent to prepare a drug suspension comprising the drug substance suspended in a mixture of the drug solvent and the anti-solvent, wherein the drug solvent and the anti-solvent are miscible;
- c) slowly adding to the drug suspension, an excipient solution comprising a co-precipitating excipient solubilized in a non-aqueous solvent, wherein the non-aqueous solvent is miscible with the drug solvent and the anti-solvent.

As another aspect, the present invention provides a pharmaceutical composition comprising a co-precipitate having a core comprising the drug substance and one or more co-precipitant layers distributed around the core, wherein the co-precipitant layers comprise a co-precipitating excipient, and wherein the co-precipitate is prepared by the process comprising the steps of:

- a) solubilizing the drug substance in a drug solvent to prepare a drug solution;
- b) admixing the drug solution with an anti-solvent to prepare a drug suspension comprising the drug substance suspended in a mixture of the drug solvent and the anti-solvent, wherein the drug solvent and the anti-solvent are miscible;
- c) slowly adding to the drug suspension, an excipient solution comprising a co-precipitating excipient solubilized in a non-aqueous solvent, wherein

the non-aqueous solvent is miscible with the drug solvent and the anti-solvent.

As another aspect, the present invention provides another pharmaceutical composition comprising a co-precipitate having a core comprising (E)-4-(1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid nonaethylene glycol methyl ether ester or a solvate thereof and one or more co-precipitant layers distributed around said core.

- 10 As another aspect, the present invention provides another process for preparing an aqueous-based pharmaceutical formulation comprising a non-crystalline, solid drug substance having low solubility in aqueous media. The method comprises the steps of:
- 15 a) solubilizing the drug substance in a drug solvent to prepare a drug solution;
 - b) admixing the drug solution with an anti-solvent to prepare a drug suspension comprising the drug substance suspended in a mixture of the drug solvent and the anti-solvent, wherein the drug solvent and the anti-solvent are miscible;
 - 20 c) slowly adding to the drug suspension, an excipient solution comprising a co-precipitating excipient solubilized in a non-aqueous solvent, to prepare a co-precipitate, wherein the non-aqueous solvent is miscible with the drug solvent and the anti-solvent;
 - d) isolating the co-precipitate; and
 - 25 e) admixing the co-precipitate with a pharmaceutically acceptable aqueous media to provide an aqueous-based pharmaceutical formulation.

As another aspect, the present invention provides a solid particulate drug substance produced by a process comprising the steps of:

- a) solubilizing the drug substance in a drug solvent to prepare a drug solution;
 - 5 b) admixing the drug solution with an anti-solvent to prepare a drug suspension comprising the drug substance suspended in a mixture of the drug solvent and the anti-solvent, wherein the drug solvent and the anti-solvent are miscible;
 - c) slowly adding to the drug suspension, an excipient solution comprising
10 a co-precipitating excipient solubilized in a non-aqueous solvent, to prepare a co-precipitate, wherein the non-aqueous solvent is miscible with the drug solvent and the anti-solvent; and
 - d) isolating the co-precipitate.
- 15 These and other aspects of the invention are described in further detail in the description and examples which follow.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is an illustration of a co-precipitate particle produced according to a
20 process of the invention.

Figure 2 is an illustration of a co-precipitate particle produced according to a process of the invention.


DETAILED DESCRIPTION OF THE INVENTION

25 The present invention provides processes for the preparation of a particulate form of a non-crystalline, solid drug substance. As such, the present invention provides methods for improving the physical properties, and particularly the handling, of a non-crystalline, solid drug substance by providing processes for converting the non-crystalline, solid drug substance
30 into particulate form.

The processes of the present invention may be employed to prepare co-precipitates of a variety of non-crystalline, solid drug substances. In particular, the processes of the present invention are useful for converting tacky, or wax-like drug substances or amorphous drug substances into a more free-flowing, particulate form.

The processes of the present invention are particularly useful when the drug substance is a wax-like drug substance.

In one embodiment of the present invention, the drug substance is a compound of formula (I):



wherein:

X is -O- or -NH-;

Q is $(-CH_2-)_p$, $(-CH=CH-)_p$, or $(-C\equiv C-)_p$ where p is an integer of from 1 to 4;

R^1 is H or methyl;

R^2 and R^3 independently represent O or S;

n is an integer of 1 to 50;

and R is H or methyl

or a solvate thereof.

Specific examples of compounds of formula (I) include but are not limited to (E)-4-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid nonaethylene glycol methyl ether ester;

(E)-4-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid decaethylene glycol methyl ether ester;

- (E)-3-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid nonaethylene glycol methyl ether ester;
- (E)-4-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid nonaethylene glycol methyl ether amide;
- 5 (E)-4-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)benzoic acid nonaethylene glycol methyl ether ester;
- (E)-4-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid triethylene glycol methyl ether ester;
- (E)-4-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid polyethylene glycol (n=7.2) methyl ether ester;
- 10 (E)-4-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid tetraethylene glycol methyl ether ester;
- (E)-4-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid pentaethylene glycol methyl ether ester;
- 15 (E)-4-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid hexaethylene glycol methyl ether ester;
- (E)-4-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid heptaethylene glycol methyl ether ester;
- (E)-4-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid octaethylene glycol methyl ether ester;
- 20 (E)-4-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid polyethylene glycol (n=11.7) methyl ether ester;
- (E)-4-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid hexaethylene glycol ester;
- 25 (E)-4-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid polyethylene glycol (n=23.9) methyl ether ester;
- (E)-4-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid polyethylene glycol (n=41.5) methyl ether ester;
- (E)-4-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid polyethylene glycol (n=15) methyl ether ester;
- 30

(E)-4-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)
cinnamic acid polyethylene glycol (n=32.2) ester;

(E)-4-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)
cinnamic acid polyethylene glycol (n=18.9) ester;

5 (E)-4-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)
cinnamic acid polyethylene glycol (n=13) ester;

(E)-3-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)
benzoic acid nonaethylene glycol methyl ether ester;

10 (E)-2-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)
benzoic acid nonaethylene glycol methyl ether ester;

(E)-4-(1,3-Bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-6-oxo-2-thioxo--9H-purin-
8-yl) cinnamic acid nonaethylene glycol methyl ether ester;
and solvates thereof.

15 In one particular embodiment of the present invention the drug substance is
(E)-4-(1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-
yl)cinnamic acid nonaethylene glycol methyl ether ester or a solvate thereof.

The processes of the present invention are further advantageous for
20 improving the stability of compounds which are susceptible to degradation by
aerial oxidation. In particular, the compounds of formula (I) are known to be
subject to degradation by aerial oxidation. The susceptibility to aerial
oxidation of the compound is reduced by the co-precipitates prepared
according to the present invention because of the intimate incorporation of
25 the drug substance in the co-precipitate, which thereby reduces the surface
area exposed to aerial oxidation.

The compounds of formula (I) may be prepared according to the processes
described in U.S. Patent No. 6,355,646 to Daluge, the subject matter of which
30 is incorporated herein by reference in its entirety.

The drug substance may comprise two or more therapeutically effective agents in combination, provided that the agents are compatible (i.e., the agents are not deleterious to each other in the processes of the present invention).

5

Process 1

In one embodiment of the present invention, a particulate form of a non-crystalline, solid drug substance may be prepared by the process comprising the steps of:

- 10 a) slowly adding a co-precipitant solution comprising the drug substance and a co-precipitating excipient solubilized in a non-aqueous solvent, to a slurry comprising a core excipient dispersed in an anti-solvent, to prepare a co-precipitate, wherein the non-aqueous solvent and the anti-solvent are miscible; and
- 15 b) isolating the co-precipitate.

Conveniently any conventional pharmaceutically acceptable excipient may be employed as the co-precipitating excipient, provided that it is compatible with the drug substance in solution. Suitable co-precipitating excipients include

20 but are not limited to sugars, sugar alcohols, polymers, starches, salts and mixtures thereof. Particular examples of suitable co-precipitating excipients are selected from sorbitol, sucrose, glucose, fructose, lactose, xylitol, maltodextrin, hydroxypropylmethylcellulose (HPMC), polyvinylpyrrolidone, saccharin, starch 1500, sodium chloride and mixtures thereof. In one

25 embodiment, the co-precipitating excipient is selected from sorbitol, sucrose, glucose, fructose, lactose, xylitol, maltodextrin and mixtures thereof. In one particular embodiment, the co-precipitating excipient is sorbitol.

The non-aqueous solvent into which the drug substance and the co-

30 precipitating excipient are solubilized may include any suitable non-aqueous solvent in which both the drug substance and the co-precipitating excipient

substantially completely dissolve. If necessary or desired, increased temperature may be employed to facilitate or expedite the solubilization of the drug substance and/or the co-precipitating excipient in the non-aqueous solvent. Examples of suitable non-aqueous solvents for use in the processes of the present invention include but are not limited to organic acids, alcohols, polar aprotic solvents, and mixtures thereof.

In one embodiment, the non-aqueous solvent is selected from acetic acid, propionic acid, formic acid, dimethylsulfoxide, dimethylformamide, ethanol, methanol and mixtures thereof. In one particular embodiment, the non-aqueous solvent is acetic acid.

In one embodiment of the present invention the co-precipitant solution further comprises an amount of drug substance stabilizer which is sufficient to increase the shelf-life of the drug substance in a pharmaceutical composition. Pharmaceutically acceptable drug substance stabilizers are known in the art and may be employed for this purpose. The choice of the particular drug substance stabilizer will depend upon the particular drug substance. In one embodiment, when the drug substance is a compound of formula (I) above, particularly when the drug substance is (E)-4-(1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid nonaethylene glycol methyl ether ester or a solvate thereof, the drug substance stabilizer is butylated hydroxy toluene (BHT).

When the drug substance stabilizer is employed in the co-precipitant solution, it becomes incorporated into the resulting co-precipitate.

The amount of drug substance stabilizer to be incorporated will depend upon the particular drug substance and drug substance stabilizer chosen and will be apparent to those skilled in the art of pharmaceutical development. In one embodiment, the amount of drug substance stabilizer is from about 1

ppm to about 1000 ppm with respect to the drug substance. In one embodiment, the amount of drug substance stabilizer is from about 1 ppm to about 750 ppm with respect to the drug substance. In one particular embodiment, the drug substance stabilizer is present in an amount of from
5 about 10 ppm to about 500 ppm with respect to the amount of drug substance.

The co-precipitant solution is then added slowly to a slurry comprising a core excipient dispersed in an anti-solvent. The core excipient may be any
10 pharmaceutically acceptable, solid excipient. Examples of suitable core excipients include but are not limited to sugars, sugar alcohols, starches, salts and mixtures thereof. Particular examples of suitable core excipients are selected from sorbitol, sucrose, glucose, fructose, lactose, xylitol, maltodextrin, saccharin, sodium chloride and mixtures thereof. In one
15 embodiment, the core excipient is sorbitol.

As used herein "anti-solvent" refers to a liquid in which the drug substance and the co-precipitating excipients are substantially completely insoluble. The anti-solvent should be chosen such that it is miscible with the non-aqueous solvent and allows robust recovery (>85%) of the co-precipitate. As used
20 herein, the term "miscible" refers to the property of the solvents to dissolve in each other such that a single-phase solution results from the combination of the non-aqueous solvent and the anti-solvent. Suitable anti-solvents are known in the art of co-precipitation and include, for example alkane solvents. Specific examples of suitable anti-solvents include but are not limited to
25 cyclohexane, isohexane, heptane, iso-octane and mixtures thereof. In one embodiment, the anti-solvent is iso-octane.

The amount of drug substance, co-precipitating excipient and core excipient which are employed to prepare the co-precipitate of the present invention will
30 depend upon the particular drug substance and excipients selected. Generally, the amount of drug substance, co-precipitating excipient and core

excipient will be sufficient to yield a co-precipitate (i.e., product) having a ratio of drug substance to combined excipients (i.e., co-precipitating excipient + core excipient) of from about 1:100 to about 50:50. In one embodiment, the ratio of drug substance to combined excipients (i.e., co-precipitating
5 excipient + core excipient) in the co-precipitate product is from about 15:85 to about 40:60. In one embodiment, the ratio of drug substance to combined excipients (i.e., co-precipitating excipient + core excipient) is about 25:75.

Conveniently, the addition of the co-precipitant solution to the slurry may be
10 carried out under ambient conditions. However, the addition may, if desired be carried out at reduced temperatures as well. The co-precipitant solution is added to the slurry slowly, optionally while stirring. In one embodiment, the co-precipitant solution is added drop-wise to the slurry, optionally while
15 stirring.

The addition of the co-precipitant solution to the slurry comprising the core excipient in the anti-solvent, results in the formation of a co-precipitate comprising the drug substance, the co-precipitating excipient and the core excipient. Without wishing to be bound by any particular theory, it is
20 presently believed that the resultant co-precipitate, as illustrated in **Figure 1**, comprises a core of excipient **1** having dispersed thereon one or more drug layers **2** comprised of drug substance **3** and co-precipitating excipient **4**.

The one or more drug layers dispersed around the core are not typically
25 uniform in thickness and may vary. The resulting co-precipitate exhibits improved physical properties, particularly in terms of handling. It is a finely divided material with flow properties resembling those of the co-precipitating excipient. More specifically, the resulting co-precipitate is a free-flowing particulate or powder. In the case of a wax-like drug substance, the resulting
30 co-precipitate no longer exhibits the tacky, wax-like characteristics of the original drug substance. Thus, in another aspect, the present invention

provides a process for improving the physical properties of a non-crystalline, solid drug substance.

According to one specific embodiment of the present invention, the process for preparing the co-precipitate comprises slowly adding a co-precipitant solution comprising (E)-4-(1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid nonaethylene glycol methyl ether ester or a solvate thereof and sorbitol solubilized in acetic acid, to a slurry comprising sorbitol dispersed in iso-octane, to prepare a co-precipitate.

10

In another embodiment, the present invention provides a solid particulate drug substance produced by a process comprising the steps of:

- a) slowly adding a co-precipitant solution comprising the drug substance and a co-precipitating excipient solubilized in a non-aqueous solvent, to a slurry comprising a core excipient dispersed in an anti-solvent, to prepare a co-precipitate, wherein the non-aqueous solvent and the anti-solvent are miscible; and
- b) isolating the co-precipitate.

15

20 Process 2

According to another embodiment, the co-precipitate may be produced by a second process, which comprises the steps of:

- a) solubilizing the drug substance in a drug solvent to prepare a drug solution;
- b) admixing the drug solution with an anti-solvent to prepare a drug suspension comprising the drug substance suspended in a mixture of the drug solvent and the anti-solvent, wherein the drug solvent and the anti-solvent are miscible;
- c) slowly adding to the drug suspension, an excipient solution comprising a co-precipitating excipient solubilized in a non-aqueous solvent, to

25

30

prepare a co-precipitate, wherein the non-aqueous solvent is miscible with the drug solvent and the anti-solvent; and

d) isolating the co-precipitate.

- 5 The choice of drug solvent will depend upon the particular drug substance chosen. Generally, the drug substance should be substantially completely soluble in the drug solvent. For example, up to about 1 g of the drug substance should solubilize in about 5-10 mL of the drug solvent. Heating may be employed to facilitate or expedite solubilization of the drug substance
- 10 in the drug solvent. In addition, the drug solvent should be miscible with the anti-solvent. Specific examples of suitable drug solvents for drugs which possess low solubility in aqueous media (such as for example the compounds of formula (I)) include but are not limited to chlorinated solvents, polar solvents, polar aprotic solvents, alcohols and mixtures thereof. More
- 15 specifically, suitable drug solvents include but are not limited to dichloromethane, ethylacetate, tetrahydrofuran, dimethylformamide, dimethylsulfoxide, methanol, ethanol, isopropanol and mixtures thereof. In one embodiment, the drug solvent is dichloromethane.
- 20 The drug solution may further comprise a drug substance stabilizer as described above.

Suitable anti-solvents are described above.

- 25 It is desirable to admix the drug solution and the anti-solvent while stirring to facilitate the formation of the drug suspension. The step of admixing the drug solution and the anti-solvent may conveniently be carried out at ambient temperature or pressure, but elevated temperature and/or pressure may also be employed. If desired, during the preparation of the drug substance
- 30 suspension, the anti-solvent may be removed and replaced with fresh anti-solvent.

The excipient solution which is added to the drug suspension comprises a co-precipitating excipient solubilized in a non-aqueous solvent. Suitable co-precipitating excipients are described above. The non-aqueous solvent
5 should be chosen so that it is miscible with both the drug solvent and the anti-solvent such that a combination of the three solvents results in a single-phase solution. Accordingly, the choice of each of the drug solvent, anti-solvent and non-aqueous solvent will depend upon each other. Suitable non-aqueous solvents for use in this process of the present invention are
10 described above.

The amount of drug substance and co-precipitating excipient which are employed to prepare the co-precipitate of the present invention will depend upon the particular drug substance and excipient selected. Generally, the
15 amount of drug substance and co-precipitating excipient will be sufficient to yield a co-precipitate (i.e., product) having a ratio of drug substance to co-precipitating excipient of from about 1:100 to about 50:50. In one embodiment, the ratio of drug substance to co-precipitating excipient in the co-precipitate product is from about 15:85 to about 40:60. In one
20 embodiment, the ratio of drug substance to co-precipitating excipient is about 25:75.

Conveniently, the addition of the excipient solution to the drug suspension may be carried out under ambient conditions. However, the addition may, if
25 desired be carried out at reduced temperatures as well. If necessary or desired the reaction may be carried out while stirring. The addition of the excipient solution to the drug suspension should be carried out slowly, and in one embodiment, the addition is drop-wise.

30 The addition of the excipient solution to the drug suspension, results in the formation of a co-precipitate comprising the drug substance and the co-

precipitating excipient. Without wishing to be bound by any particular theory, it is presently believed that the resultant co-precipitate, as illustrated in **Figure 2**, comprises a core of drug substance **1** having dispersed thereon one or more layers comprised of co-precipitating excipient **2**. The layers of the co-precipitating excipient are not typically of uniform thickness and may vary. The resulting co-precipitate exhibits improved physical properties, particularly in terms of handling. It is a finely divided material with flow properties resembling those of the co-precipitating excipient. More specifically, the resulting co-precipitate is a free-flowing particulate or powder. In the case of a wax-like drug substance, the resulting co-precipitate no longer exhibits the tacky, wax-like characteristics of the original drug substance. Thus, in another aspect, the present invention provides another process for improving the physical properties of a non-crystalline, solid drug substance.

15

In one specific embodiment of the present invention, the process for preparing the co-precipitate comprises the steps of:

- a) solubilizing (E)-4-(1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid nonaethylene glycol methyl ether ester or a solvate thereof in dichloromethane to prepare a drug solution;
- b) admixing the drug solution with iso-octane to prepare a drug suspension comprising (E)-4-(1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid nonaethylene glycol methyl ether ester or a solvate thereof suspended in a mixture of dichloromethane and iso-octane; and
- c) slowly adding to the drug suspension, an excipient solution comprising sorbitol solubilized in acetic acid, to prepare a co-precipitate.

25

In another embodiment, the present invention provides a solid particulate drug substance produced by a process comprising the steps of:

30

- a) solubilizing the drug substance in a drug solvent to prepare a drug solution;
- b) admixing the drug solution with an anti-solvent to prepare a drug suspension comprising the drug substance suspended in a mixture of the drug solvent and the anti-solvent, wherein the drug solvent and the anti-solvent are miscible;
- c) slowly adding to the drug suspension, an excipient solution comprising a co-precipitating excipient solubilized in a non-aqueous solvent, to prepare a co-precipitate, wherein the non-aqueous solvent is miscible with the drug solvent and the anti-solvent; and
- d) isolating the co-precipitate.

The co-precipitate produced according to either of the foregoing processes may be isolated by any suitable means of separating the co-precipitate from the mixture of non-aqueous solvent and anti-solvent. For example, the co-precipitate may be isolated by filtering. If filtering is employed, it may be desirable to subsequently dry the co-precipitate to remove any residual solvent or anti-solvent. The optional drying step may be carried out at ambient temperature and pressure or at elevated temperature and/or reduced pressure. In another embodiment, the co-precipitate is isolated by evaporating off the non-aqueous solvent and the anti-solvent.

The co-precipitate produced according to the foregoing processes may be used alone as a pharmaceutical composition or incorporated into a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients or carriers. In one particular embodiment, the present invention provides a pharmaceutical composition comprising a co-precipitate having a core comprising a core excipient and one or more drug layers distributed around the core wherein the drug layers comprise (E)-4-(1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinna-
acid nonaethylene glycol methyl ether ester or a solvate thereof and a co-precipitating excipient.

In another particular embodiment, the pharmaceutical composition comprises a co-precipitate having a core comprising (E)-4-(1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid nonaethylene glycol methyl ether ester or a solvate thereof and one or more co-precipitant layers distributed around the core.

Pharmaceutical compositions of the co-precipitates prepared according to the processes of the present invention may conveniently be prepared using conventional pharmaceutical formulation techniques. Possible formulations include those suitable for oral, sublingual, buccal, parenteral (for example subcutaneous, intramuscular, or intravenous), rectal, topical including transdermal, intranasal and inhalation administration. The most suitable means of administration for a particular patient will depend on the nature and severity of the condition being treated and on the nature of the active compound, with the optimum route of administration being within the discretion of the attendant physician.

Formulations suitable for oral administration may be provided as discrete units, such as tablets, capsules, cachets, lozenges, each containing a predetermined amount of the active compound; as powders or granules; as solutions or suspensions in aqueous or non-aqueous liquids; or as oil-in-water or water-in-oil emulsions.

Formulations suitable for sublingual or buccal administration include lozenges comprising the active compound and, typically a flavoured base, such as sugar and acacia or tragacanth and pastilles comprising the active compound in an inert base, such as gelatine and glycerine or sucrose acacia.

Formulations suitable for parenteral administration typically comprise sterile aqueous solutions containing a predetermined concentration of the active compound; the solution is preferably isotonic with the blood of the intended

recipient. Although such solutions are preferably administered intravenously, they may also be administered by subcutaneous or intramuscular injection.

5 Formulations suitable for rectal administration are preferably provided as unit-dose suppositories comprising the active ingredient in one or more solid carriers forming the suppository base, for example, cocoa butter.

10 Formulations suitable for topical or intranasal application include ointments, creams, lotions, pastes, gels, sprays, aerosols and oils. Suitable carriers for such formulations include petroleum jelly, lanolin, polyethyleneglycols, alcohols, and combinations thereof. The active ingredient is typically present in such formulations at a concentration of from 0.1 to 15% w/w.

15 Formulations of the invention may be prepared by any suitable method, typically by uniformly and intimately admixing the active compound with liquids or finely divided solid carriers or both, in the required proportions and then, if necessary, shaping the resulting mixture into the desired shape.

20 For example a tablet may be prepared by compressing an intimate mixture comprising a powder or granules of the active ingredient and one or more optional ingredients, such as a binder, lubricant, inert diluent, or surface active dispersing agent, or by moulding an intimate mixture of powdered active ingredient and inert liquid diluent.

25 Suitable formulations for administration by inhalation include fine particle dusts or mists which may be generated by means of various types of metered dose pressurised aerosols, nebulisers, or insufflators.

30 For pulmonary administration via the mouth, the particle size of the powder or droplets is typically in the range 0.5 -10 μ m, preferably 1-5 μ m, to ensure

delivery into the bronchial tree. For nasal administration, a particle size in the range 10-500 μ m is preferred to ensure retention in the nasal cavity.

5 Metered dose inhalers are pressurized aerosol dispensers, typically containing a suspension or solution formulation of the active ingredient in a liquefied propellant. During use, these devices discharge the formulation through a valve adapted to deliver a metered volume, typically from 10 to 150 μ l, to produce a fine particle spray containing the active ingredient. Suitable propellants include certain chlorofluorocarbon compounds, for example, 10 dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane and mixtures thereof. The formulation may additionally contain one or more co-solvents, for example, ethanol surfactants, such as oleic acid or sorbitan trioleate, anti-oxidants and suitable flavouring agents.

15 Nebulisers are commercially available devices that transform solutions or suspensions of the active ingredient into a therapeutic aerosol mist either by means of acceleration of a compressed gas typically air or oxygen, through a narrow venturi orifice, or by means of ultrasonic agitation. Suitable formulations for use in nebulisers consist of the active ingredient in a liquid 20 carrier and comprising up to 40% w/w of the formulation, preferably less than 20%w/w. The carrier is typically water or a dilute aqueous alcoholic solution, preferably made isotonic with body fluids by the addition of, for example, sodium chloride. Optional additives include preservatives if the formulation is not prepared sterile, for example, methyl hydroxy-benzoate, 25 anti-oxidants, flavouring agents, volatile oils, buffering agents and surfactants.

Suitable formulations for administration by insufflation include finely comminuted powders which may be delivered by means of an insufflator or 30 taken into the nasal cavity in the manner of a snuff. In the insufflator, the powder is contained in capsules or cartridges, typically made of gelatin or

plastic, which are either pierced or opened *in situ* and the powder delivered by air drawn through the device upon inhalation or by means of a manually-operated pump. The powder employed in the insufflator consists either solely of the active ingredient or of a powder blend comprising the active ingredient, a suitable powder diluent, such as lactose, and an optional surfactant. The active ingredient typically comprises from 0.1 to 100 w/w of the formulation.

The co-precipitates produced according to the processes of the present invention are particularly suited to preparing aqueous-based pharmaceutical formulations comprising a non-crystalline, solid drug substance having a low solubility in aqueous media. According to one embodiment of the invention, an aqueous-based pharmaceutical formulation of such a drug substance is prepared by a process comprising the steps of:

- a) slowly adding a co-precipitant solution comprising the drug substance and a co-precipitating excipient solubilized in a non-aqueous solvent, to a slurry comprising a core excipient dispersed in an anti-solvent, to prepare a co-precipitate, wherein the non-aqueous solvent and the anti-solvent are miscible;
- b) isolating the co-precipitate; and
- c) admixing the co-precipitate with a pharmaceutically acceptable aqueous media to provide an aqueous-based pharmaceutical formulation.

In another embodiment, the process for preparing an aqueous-based pharmaceutical formulation comprising a non-crystalline, solid drug substance having a low solubility in aqueous media comprises the steps of:

- a) solubilizing the drug substance in a drug solvent to prepare a drug solution;
- b) admixing the drug solution with an anti-solvent to prepare a drug suspension comprising the drug substance suspended in a mixture of drug solvent and anti-solvent, wherein the drug solvent and the anti-solvent are miscible;

- c) slowly adding to the drug suspension, an excipient solution comprising a co-precipitating excipient solubilized in a non-aqueous solvent, to prepare a co-precipitate, wherein the non-aqueous solvent is miscible with the drug solvent and the anti-solvent;
- 5 d) isolating the co-precipitate; and
- e) admixing the co-precipitate with a pharmaceutically acceptable aqueous media to provide an aqueous-based pharmaceutical formulation.

- 10 Suitable aqueous media include conventional pharmaceutically acceptable aqueous solvents such as water, saline, solutions of cyclodextrin in water, solutions of glucose in water and mixtures thereof. Such aqueous formulations may optionally further include one or more pH buffers and/or other conventional pharmaceutical additives.
- 15 The co-precipitates and pharmaceutical compositions containing the same which are prepared according to the processes of the present invention have use in medicinal therapy. In particular, the co-precipitates and pharmaceutical compositions wherein the drug substance is a compound of formula (I) are useful for the treatment of inflammatory conditions and
- 20 immune disorders associated with the infiltration of leukocytes into inflamed tissue, and particularly for the treatment of those conditions described in U.S. Patent No. 6,355,646, the subject matter of which is incorporated herein by reference in its entirety. In particular, such co-precipitates and compositions are useful for the treatment of inflammatory bowel disease, irritable bowel
- 25 syndrome, functional dyspepsia, periodontal disease, eczema, rheumatoid arthritis and asthma.

Accordingly, the present invention, in another embodiment provides methods for the treatment of these conditions or diseases in a mammal, particularly a

30 human. The methods comprise the step of administering a therapeutically effective amount of a co-precipitate according to the processes of the present

invention. As used herein, the term "treatment" refers to alleviating the specified condition, eliminating or reducing the symptoms of the condition, slowing or eliminating the progression of the condition and preventing or delaying the re-occurrence of the condition in a previously afflicted subject.

5

The precise therapeutically effective amount of the co-precipitate will depend on a number of factors including, but not limited to, the drug substance and condition or disease being treated, the age and weight of the subject being treated, the severity of the condition or disease being treated, the nature of the formulation, and the route of administration, and will ultimately be at the discretion of the attendant physician or veterinarian. Suitable doses of compounds of formula (I) will be apparent to those skilled in the art based upon the disclosure in U.S. Patent No. 6,355,646.

10

15 The present invention is further illustrated by, but is not limited to, the following examples. In the following examples, "Compound 1" refers to (E)-4-(1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnaemic acid nonaethylene glycol methyl ether ester; and "iso-octane" is also known as 2,2,4-trimethylpentane.

20

Example 1: Co-Precipitation with Sorbitol 1

A warm (30-40°C) solution of Compound 1 (2.0g, 1wt) and Sorbitol (3g, 1.5wt) in acetic acid (12ml, 6vol) is added slowly over 20min to a stirred mixture of Sorbitol (3g, 1.5wt) and iso-octane (150ml, 75vol) at room temperature (20-25°C). The resulting mixture is stirred at room temperature for 30min and the solids isolated by filtration. The solid product is washed with iso-octane (3 x 10ml, 3 x 5vol) and dried *in vacuo* at 40°C. Recovery: 7.5g, 3.75wt.

25

Analysis: Analysis showed 22%w/w loading of Compound on Sorbitol. (ie: 1g of Compound 1 is contained in 4.48g of co-precipitate).

30

Example 2: Co-Precipitation with Sorbitol 2

A warm (30–40°C) solution of Compound 1 (3g, 1wt) and Sorbitol (3g, 1wt) in acetic acid (12ml, 4vol) is added slowly over 20min to a stirred mixture of Sorbitol (3g, 1wt) and iso-octane (200ml, 67vol) at room temperature (20–25°C). The resulting mixture is stirred at room temperature for 30min and the solids isolated by filtration. The solid product is washed with iso-octane (2 x 15ml, 2 x 5vol) and dried *in vacuo* at 40°C. Recovery: 8.4g, 2.8wt. Analysis: Analysis showed 32%w/w loading of Compound 1 on Sorbitol. (ie: 1g of Compound 1 is contained in 3.16g of co-precipitate).

Example 3: Co-Precipitation with Xylitol 1

A warm (30–40°C) solution of Compound 1 (1g, 1wt) and Xylitol (1.5g, 1.5wt) in acetic acid (6ml, 6vol) is added slowly to a stirred mixture of Xylitol (1.5g, 1.5wt) and iso-octane (75ml, 75vol) at room temperature (20–25°C). The resulting mixture is stirred at room temperature for 20min and the solids isolated by filtration. The solid product is washed with iso-octane (2 x 15ml, 2 x 15vol) and dried *in vacuo* at 40°C. Recovery: 3.7g, 3.7wt. Analysis: The product was a finely-divided solid which was observed to be slightly more “sticky” than the analogous product with Sorbitol.

Example 4: Co-Precipitation with Xylitol 2

A warm (85–90°C) solution of Compound 1 (1g, 1wt) and Xylitol (1.5g, 1.5wt) in denatured ethanol (IMS, 7.5ml, 7.5vol) is added slowly to a stirred mixture of Xylitol (1.5g, 1.5wt) and iso-octane (75ml, 75vol) at room temperature (20–25°C). The resulting mixture is stirred at room temperature for 30min and the solids isolated by filtration. The solid product is washed with iso-octane (2 x 25ml, 2 x 25vol) and dried *in vacuo* at 40°C. Recovery: 3.7g, 3.7wt.

Analysis: This yielded a product very similar to **Example 3**.

Example 5: Co-Precipitation With Sorbitol and Maltodextrin

A warm (30-40°C) solution of Compound 1 (1g, 1wt) and Sorbitol (1.5g, 1.5wt) in acetic acid (7.5ml, 7.5vol) is added slowly over 20min to a stirred mixture of maltodextrin (1.5g, 1.5wt) and iso-octane (75ml, 75vol) at room temperature (20-25°C). The resulting mixture is stirred at room temperature for 30min and the solids isolated by filtration. The solid product is washed with iso-octane (2 x 10ml, 2 x 10vol) and dried *in vacuo* at 40°C. Recovery: 3.7g, 3.7wt.

Analysis: Analysis showed 22%w/w loading of Compound 1 on Sorbitol/maltodextrin. (ie: 1g of Compound 1 is contained in 4.5g of co-precipitate).

Example 6: Co-Precipitation with Xylitol and Maltodextrin

A warm (30-40°C) solution of Compound 1 (1g, 1wt) and Xylitol (1.5g, 1.5wt) in acetic acid (7.5ml, 7.5vol) is added slowly over 20min to a stirred mixture of maltodextrin (1.5g, 1.5wt) and iso-octane (75ml, 75vol) at room temperature (20-25°C). The resulting mixture is stirred at room temperature for 30min and the solids isolated by filtration. The solid product is washed with iso-octane (2 x 10ml, 2 x 10vol) and dried *in vacuo* at 40°C. Recovery: 3.7g, 3.7wt.

Analysis: Analysis showed 22%w/w loading of Compound 1 on Xylitol / maltodextrin. (ie: 1g of Compound 1 is contained in 4.5g of co-precipitate).

Example 7: Co-Precipitation with Sorbitol and Xylitol

A warm (30-40°C) solution of Compound 1 (1g, 1wt) and Sorbitol (1.5g, 1.5wt) in acetic acid (7ml, 7vol) is added slowly over 20min to a stirred mixture of Xylitol (1.5g, 1.5wt) and iso-octane (75ml, 75vol) at room temperature (20-25°C). The resulting mixture is stirred at room temperature for 30min and the solids isolated by filtration. The solid product is washed with iso-octane (2 x 25ml, 2 x 25vol) and dried *in vacuo* at 40°C. Recovery: 3.6g, 3.6wt.

Analysis: Physical properties are very similar to Sorbitol co-precipitates of Examples 1 and 2.

Example 8: Co-Precipitation with Saccharin

- 5 A solution of Compound 1 (1g, 1wt) and Saccharin (1.5g, 1.5wt) in tetrahydrofuran (7.5ml, 7.5vol) is added slowly over 20min to a stirred mixture of Saccharin (1.5g, 1.5wt) and iso-octane (100ml, 100vol) at room temperature (20-25°C). The resulting mixture is stirred at room temperature for 30min and the solids isolated by filtration. The solid product is washed
10 with iso-octane (2 x 25ml, 2 x 25vol) and dried *in vacuo* at 40°C. Recovery: 3.6g, 3.6wt.

Analysis: Analysis showed 25%w/w loading of Compound 1 on Saccharin.

Example 9: Co-Precipitate with Sorbitol and Sodium Chloride

- 15 A warm (30-40°C) solution of Compound 1 (1g, 1wt) and Sorbitol (1.5g, 1.5wt) in acetic acid (7ml, 7vol) is added slowly over 20min to a stirred mixture of sodium chloride (1.5g, 1.5wt) and iso-octane (75ml, 75vol) at room temperature (20-25°C). During the addition the co-precipitate starts to agglomerate so the iso-octane is decanted off and replaced with fresh iso-
20 octane. The resulting mixture is stirred at room temperature for 30min and the solids isolated by filtration. The solid product is washed with iso-octane (2 x 25ml, 2 x 25vol) and dried *in vacuo* at 40°C. Recovery: 2.9g, 2.9wt.

Analysis: Analysis showed 19%w/w loading of Compound 1 on Sorbitol / sodium chloride.

25

Example 10: Co-Precipitation with Sorbitol 3

- A warm (30-40°C) solution of Compound 1 (0.5g, 1wt) and Sorbitol (0.75g, 1.5wt) in acetic acid (4ml, 8vol) is added slowly over 20min to a stirred mixture of Sorbitol (1.5g, 3wt) in Heptane (75ml, 150vol) at room
30 temperature (20-25°C). The resulting mixture is stirred at room temperature for 30min and the solids isolated by filtration. The solid product is washed

with Heptane (2 x 25ml, 2 x 50vol) and dried *in vacuo* at 40°C. Recovery: 2.6g, 2.6wt.

Analysis: Analysis showed 16%w/w loading of Compound 1 on Sorbitol.

5 Example 11: Co-Precipitation with Sorbitol at Reduced Temperature

A warm (30–40°C) solution of Compound 1 (1g, 1wt) and Sorbitol (1.5g, 1.5wt) in acetic acid (7.5ml, 7.5vol) is added slowly over 20min to a stirred mixture of Sorbitol (1.5g, 3wt) in iso-octane (75ml, 75vol) at 0 to -3°C. The resulting mixture is stirred at 0 to -3°C for 30min and the solids isolated by
10 filtration. The solid product is washed with iso-octane (2 x 25ml, 2 x 25vol) and dried *in vacuo* at 40°C. Recovery: 3.9g, 3.9wt.

Analysis: Analysis showed 22%w/w loading of Compound 1 on Sorbitol.

Example 12: Co-Precipitation Process 2

15 A solution of Compound 1 (5.3g, 1wt) in a mixture of dichloromethane (10ml, 1.9vol) and 2-propanol (5ml, 0.9vol) is added slowly over 20min to stirred iso-octane (300ml, 57vol) at room temperature. A solution of Sorbitol (15g, 2.8wt) in acetic acid (30ml, 5.7vol) is then added slowly over 20min at room temperature. The resulting mixture is stirred at room temperature for 30min
20 and the solids isolated by filtration. The solid product is washed with iso-octane (3 x 10ml, 3 x 1.9vol) and dried *in vacuo* at 45°C.

Recovery: 17.9g, 3.4wt.

Analysis: Microscopic analysis revealed Compound 1 coated with Sorbitol.

25 Example 13: Co-Precipitation Process 2

A solution of Compound 1 (5g, 1wt) in a mixture of dichloromethane (10ml, 2vol) and 2-propanol (5ml, 1vol) is added slowly over 20min to stirred iso-octane (400ml, 80vol) at room temperature. A solution of sorbitol (25g, 5wt) in acetic acid (50ml, 10vol) is then added slowly over 20min at room
30 temperature. The resulting mixture is stirred at room temperature for 30min

and the solids isolated by filtration. The solid product is washed with iso-octane (3 x 10ml, 3 x 1.9vol) and dried in vacuo at 45°C.

Example 14: Co-Precipitation Process 2 with Xylitol.

5 A solution of Compound 1 (5g, 1wt) in a mixture of dichloromethane (10ml, 2vol) and 2-propanol (5ml, 1vol) is added slowly over 20min to stirred iso-octane (300ml, 60vol) at room temperature. A solution of xylitol (15g, 3wt) in acetic acid (30ml, 6vol) is then added slowly over 20min at room temperature. The resulting mixture is stirred at room temperature for 30min
10 and the solids isolated by filtration. The solid product is washed with iso-octane (3 x 10ml, 3 x 1.9vol) and dried in vacuo at 45°C.

Example 15: Co-Precipitation Process 2

A solution of Compound 1 (5g, 1wt) in a mixture of dichloromethane (10ml, 2vol) and 2-propanol (5ml, 1vol) is added slowly over 20min to stirred
15 heptane (300ml, 60vol) at room temperature. A solution of sorbitol (15g, 3wt) in acetic acid (30ml, 6vol) is then added slowly over 20min at room temperature. The resulting mixture is stirred at room temperature for 30min and the solids isolated by filtration. The solid product is washed with heptane
20 (3 x 10ml, 3 x 1.9vol) and dried in vacuo at 45°C.

Example 16: Co-Precipitation Process 2 with BHT

A solution of Compound 1 (5g, 1wt) in a mixture of dichloromethane (10ml, 2vol) and 2-propanol (5ml, 1vol) containing butylated hydroxy-toluene (BHT)
25 (1g, 0.2wt) is added slowly over 20min to stirred iso-octane (300ml, 60vol) at room temperature. A solution of sorbitol (15g, 3wt) in acetic acid (30ml, 6vol) is then added slowly over 20min at room temperature. The resulting mixture is stirred at room temperature for 30min and the solids isolated by filtration. The solid product is washed with iso-octane (3 x 10ml, 3 x 1.9vol)
30 and dried in vacuo at 45°C.

Example 17: Suspension Formulations

Suspensions containing Compound 1 Co-precipitate as prepared according to any of Examples 1-16, are comprised of the following functional ingredients in the typical ranges indicated:

5

General Suspension Formulation Guidelines

Function	Component	Quantity %w/w
Active	Compound 1 Coprecipitate	4 - 20*
Suspending agent	Xanthan gum, Hydroxypropylmethyl cellulose, microcrystalline cellulose and carboxymethylcellulose sodium	0.1 - 5
Preservative	Sodium benzoate, methyl/propyl parabens	0.1 - 5
Wetting agent	Sodium lauryl sulphate, Tween	0.1 - 2
Antifoaming agent	Simethicone, Dimethicone	0.2 - 5
Buffering agent	Sodium citrate, sodium phosphate, sodium acetate	0.05 - 0.5
Flavours	Lemon, orange etc	0.01 - 0.1
Solvent Vehicle	Water	60 - 100
Cosolvent vehicle	Glycerol, proylene glycol	5 - 40

Suspension Formulation 1

Function	Component	Quantity (%w/w)
Active ingredient	Compound 1/Sorbitol co-precipitate	10.0*
Anti-foaming agent	Simethicone 30% emulsion	0.2 – 5.0
Preservative	Sodium benzoate	0.02 – 0.50
Flavouring agent	Lemon flavour	0.01 – 0.10
Vehicle	Citrate buffer, pH 4	to 100

Suspension Formulation 2

Function	Possible components	Quantity (%w/w)
Active ingredient	Compound 1/Sorbitol co-precipitate	10.0*
Suspending agent	Xanthan gum	0.1 – 1.0
Anti-foaming agent	Simethicone 30% emulsion,	0.2 – 5.0
Preservative	Sodium benzoate, parabens	0.02 – 0.50
Flavouring agent	Lemon flavour	0.01 – 0.10
Vehicle	Citrate buffer, pH 4	to 100

Suspension Formulation 3

Function	Possible components	Quantity (%w/w)
Active ingredient	Compound 1/Sorbitol co-precipitate	10.0*
Wetting agent	Sodium lauryl sulphate	0.1 – 2.0
Suspending agent	Xanthan gum	0.1 – 1.0
Anti-foaming agent	Simethicone 30% emulsion	0.2 – 5.0
Preservative	Sodium benzoate	0.02 – 0.50
Flavouring agent	Lemon flavour	0.01 – 0.10
Vehicle	Citrate buffer, pH 4	to 100

5

* assumes drug/sorbitol ratio 1:3, equivalent to an API suspension strength of 2.5% w/w.

CLAIMS

That Which Is Claimed Is:

1. A process for preparing a particulate form of a non-crystalline, solid drug substance comprising the steps of:
 - 5 a) slowly adding a co-precipitant solution comprising the drug substance and a co-precipitating excipient solubilized in a non-aqueous solvent, to a slurry comprising a core excipient dispersed in an anti-solvent, to prepare a co-precipitate, wherein said non-aqueous solvent and said anti-solvent are miscible;
 - 10 b) isolating said co-precipitate.
2. The process according to claim 1, wherein said drug substance is (E)-4-(1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid nonaethylene glycol methyl ether ester or a solvate thereof.
15
3. The process according to claim 1, wherein said co-precipitating excipient is selected from sorbitol, sucrose, glucose, fructose, lactose, xylitol, maltodextrin, hydroxypropylmethylcellulose, polyvinylpyrrolidone, starch 1500, sodium chloride and mixtures thereof.
20
4. The process according to claim 1, wherein said non-aqueous solvent is selected from organic acids, alcohols, polar aprotic solvents, and mixtures thereof.
- 25 5. The process according to claim 1, wherein said core excipient is selected from sorbitol, sucrose, glucose, fructose, lactose, xylitol, maltodextrin and mixtures thereof.
6. The process according to claim 1, wherein said anti-solvent is an
30 alkane solvent.

7. A process for preparing a co-precipitate of a non-crystalline, solid drug substance comprising slowly adding a co-precipitant solution comprising the drug substance and a co-precipitating excipient solubilized in a non-aqueous solvent, to a slurry comprising a core excipient dispersed in an anti-solvent, wherein said non-aqueous solvent and said anti-solvent are miscible.

8. A pharmaceutical composition comprising a co-precipitate having a core comprising core excipient and one or more drug layers distributed around said core, wherein said drug layers comprise a drug substance and a co-precipitating excipient, and wherein said co-precipitate is prepared by slowly adding a co-precipitant solution comprising said drug substance and said co-precipitating excipient solubilized in a non-aqueous solvent, to a slurry comprising said core excipient dispersed in an anti-solvent, wherein said non-aqueous solvent and said anti-solvent are miscible.

15

9. A pharmaceutical composition comprising a co-precipitate having a core comprising a core excipient and one or more drug layers distributed around said core wherein said drug layers comprise (E)-4-(1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnaemic acid nonaethylene glycol methyl ether ester or a solvate thereof and a co-precipitating excipient.

20

10. A process for preparing an aqueous-based pharmaceutical formulation comprising a non-crystalline, solid drug substance having low solubility in aqueous media, said process comprising the steps of:

25

a) slowly adding a co-precipitant solution comprising the drug substance and a co-precipitating excipient solubilized in a non-aqueous solvent, to a slurry comprising a core excipient dispersed in an anti-solvent, to prepare a co-precipitate, wherein said non-aqueous solvent and said anti-solvent are miscible;

30

b) isolating said co-precipitate; and

- c) admixing said co-precipitate with a pharmaceutically acceptable aqueous media to provide an aqueous-based pharmaceutical formulation.

- 5 11. A process for preparing a particulate form of a non-crystalline, solid drug substance comprising the steps of:
- a) solubilizing said drug substance in a drug solvent to prepare a drug solution;
 - b) admixing said drug solution with an anti-solvent to prepare a drug
10 suspension comprising said drug substance suspended in a mixture of said drug solvent and said anti-solvent, wherein said drug solvent and said anti-solvent are miscible;
 - c) slowly adding to said drug suspension, an excipient solution comprising a co-precipitating excipient solubilized in a non-aqueous solvent, to
15 prepare a co-precipitate, wherein said non-aqueous solvent is miscible with said drug solvent and said anti-solvent; and
 - d) isolating said co-precipitate.

12. The process according to claim 11, wherein said drug substance is (E)-
20 4-(1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid nonaethylene glycol methyl ether ester or a solvate thereof.

13. The process according to claim 11, wherein said drug solvent is selected from dichloromethane, ethylacetate, tetrahydrofuran,
25 dimethylformamide, dimethylsulfoxide, methanol, ethanol, isopropanol and mixtures thereof.

14. The process according to claim 11, wherein said anti-solvent is an alkane solvent.

15. The process according to claim 11, wherein said co-precipitating excipient is selected from sorbitol, sucrose, glucose, fructose, lactose, xylitol, maltodextrin, hydroxypropylmethylcellulose, polyvinylpyrrolidone, starch 1500, sodium chloride and mixtures thereof.

5

16. The process according to claim 11, wherein said non-aqueous solvent is selected from organic acids, alcohols, polar aprotic solvents, and mixtures thereof.

10 17. A process for preparing a co-precipitate of a non-crystalline, solid drug substance comprising the steps of:

a) solubilizing said drug substance in a drug solvent to prepare a drug solution;

15 b) admixing said drug solution with an anti-solvent to prepare a drug suspension comprising said drug substance suspended in a mixture of said drug solvent and said anti-solvent, wherein said drug solvent and said anti-solvent are miscible;

c) slowly adding to said drug suspension, an excipient solution comprising a co-precipitating excipient solubilized in a non-aqueous solvent, 20 wherein said non-aqueous solvent is miscible with said drug solvent and said anti-solvent.

18. A pharmaceutical composition comprising a co-precipitate having a core comprising said drug substance and one or more co-precipitant layers 25 distributed around said core, wherein said co-precipitant layers comprise a co-precipitating excipient, and wherein said co-precipitate is prepared by the process comprising the steps of:

- a) solubilizing said drug substance in a drug solvent to prepare a drug solution;
- b) admixing said drug solution with an anti-solvent to prepare a drug suspension comprising said drug substance suspended in a mixture of said drug solvent and said anti-solvent, wherein said drug solvent and said anti-solvent are miscible;
- c) slowly adding to said drug suspension, an excipient solution comprising a co-precipitating excipient solubilized in a non-aqueous solvent, wherein said non-aqueous solvent is miscible with said drug solvent and said anti-solvent.

19. A pharmaceutical composition comprising a co-precipitate having a core comprising (E)-4-(1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid nonaethylene glycol methyl ether ester or a solvate thereof and one or more co-precipitant layers distributed around said core.

20. A process for preparing an aqueous-based pharmaceutical formulation comprising a non-crystalline, solid drug substance having low solubility in aqueous media, said process comprising the steps of:

- a) solubilizing said drug substance in a drug solvent to prepare a drug solution;
- b) admixing said drug solution with an anti-solvent to prepare a drug suspension comprising said drug substance suspended in a mixture of said drug solvent and said anti-solvent, wherein said drug solvent and said anti-solvent are miscible;
- c) slowly adding to said drug suspension, an excipient solution comprising a co-precipitating excipient solubilized in a non-aqueous solvent, to prepare a co-precipitate, wherein said non-aqueous solvent is miscible with said drug solvent and said anti-solvent;
- d) isolating said co-precipitate; and

- e) admixing said co-precipitate with a pharmaceutically acceptable aqueous media to provide an aqueous-based pharmaceutical formulation.


ABSTRACT

The present invention provides processes for preparing co-precipitates of non-crystalline, solid drug substances, such as (E)-4-(1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid nonaethylene glycol methyl ether ester and solvates thereof.

5


Title: Process For Preparing A Co-Precipitate Of A
Non-Crystalline Solid Drug Substance
Inventor: R. Barrett et al.
Atty Docket No.: PB60536P

Figure 1



Title: Process For Preparing A Co-Precipitate Of A
Non-Crystalline Solid Drug Substance
Inventor: R. Barrett et al.
Atty Docket No.: PB60536P

Figure 2



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.